Barclays
MDGL icon

Barclays’s Madrigal Pharmaceuticals MDGL Stock Holding History

Barclays’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-797
Closed -$28K – 6324
2015
Q3 		$28K Sell
797
-106
-12% -$7.65K ﹤0.01% 5311
2015
Q2 		$63K Buy
903
+517
+134% +$43.4K ﹤0.01% 5007
2015
Q1 		$14K Buy
386
+49
+15% +$4.2K ﹤0.01% 6032
2014
Q4 		$24K Sell
337
-277
-45% -$28.6K ﹤0.01% 6214
2014
Q3 		$65K Sell
614
-120
-16% -$16.7K ﹤0.01% 5659
2014
Q2 		$103K Sell
734
-1,077
-59% -$157K ﹤0.01% 5387
2014
Q1 		$254K Sell
1,811
-1,003
-36% -$198K ﹤0.01% 4569
2013
Q4 		$493K Buy
2,814
+2,363
+524% +$433K ﹤0.01% 4108
2013
Q3 		$95K Sell
451
-1,126
-71% -$240K ﹤0.01% 5650
2013
Q2 		$275K Buy
+1,577
New +$411K ﹤0.01% 4865

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's MDGL Position: Q1 2026 in Review

Barclays reduced its Madrigal Pharmaceuticals (MDGL) stake by 91% in Q1 2026, selling an estimated $16.9M and leaving 3,376 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

Barclays first reported a position in MDGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.5M in Q4 2022. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Barclays held 3,376 shares of Madrigal Pharmaceuticals worth $1.77M as of Q1 2026.
  • Barclays sold 35,344 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2425 holding.
  • Barclays first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Madrigal Pharmaceuticals position peaked at $25.5M in Q4 2022.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.